Literature DB >> 31201795

Time Trade-off Utility Values in Noninfectious Uveitis.

Katherine M Niemeyer1, John A Gonzales2, Thuy Doan2, Erica N Browne1, Maya M Rao1, Nisha R Acharya3.   

Abstract

PURPOSE: To investigate time trade-off (TTO) utility values in patients with noninfectious uveitis and determine whether patient demographics and clinical characteristics are associated with utility scores.
DESIGN: Time trade-off utility analysis.
METHODS: Setting: A tertiary care uveitis center in San Francisco, California, USA. PATIENT POPULATION: One hundred and four consecutive adults with noninfectious uveitis, enrolled between November 2016 and February 2017. MAIN OUTCOME MEASURES: TTO utility values, as collected by an interviewer-guided survey. Information regarding general health, ocular symptoms, and religion was also collected and medical record review was conducted to record anatomic location of uveitis, disease activity, visual acuity, and treatments. Multivariable regression analysis with backward selection was used to identify variables associated with TTO values.
RESULTS: Median TTO score was 0.975 (interquartile range [IQR]: 0.8-1.0), corresponding to trading a median 1.28 years of remaining life for healthy eyes (IQR: 0-6.29). Regression analysis revealed that worse eye visual acuity, >6 months of oral corticosteroid use, and current antidepressant use were associated with lower TTO scores (P = .008, P = .006, P = .008, respectively), controlling for age and sex. In particular, patients who had been taking oral corticosteroids for more than 6 months, regardless of dose, were 10.5 times more likely to trade 20% or more years of remaining life (TTO ≤0.8) than patients not taking oral corticosteroids (95% confidence interval: 2.3, 48.1; P = .002).
CONCLUSIONS: Patients with noninfectious uveitis had measurable, though modest, reductions in quality of life, as assessed by TTO, and these decreases were significantly associated with visual acuity in the worse eye and long-term oral corticosteroid use.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31201795      PMCID: PMC6888854          DOI: 10.1016/j.ajo.2019.06.005

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  55 in total

1.  Distress, depression and coping in HLA-B27-associated anterior uveitis with focus on gender differences.

Authors:  S M Maca; A W Schiesser; A Sobala; K Gruber; G Pakesch; C Prause; T Barisani-Asenbauer
Journal:  Br J Ophthalmol       Date:  2010-10-22       Impact factor: 4.638

Review 2.  Constructive and unconstructive repetitive thought.

Authors:  Edward R Watkins
Journal:  Psychol Bull       Date:  2008-03       Impact factor: 17.737

3.  Visual functioning and general health status in patients with uveitis.

Authors:  R M Schiffman; G Jacobsen; S M Whitcup
Journal:  Arch Ophthalmol       Date:  2001-06

4.  Utility and uncorrected refractive error.

Authors:  Nina Tahhan; Eric Papas; Timothy R Fricke; Kevin D Frick; Brien A Holden
Journal:  Ophthalmology       Date:  2013-05-09       Impact factor: 12.079

5.  Visual Functioning and Health-related Quality-of-Life are Compromised in Patients with Uveitis.

Authors:  Michelle M Hui; Denis Wakefield; Ilesh Patel; Erin Cvejic; Peter J McCluskey; John H Chang
Journal:  Ocul Immunol Inflamm       Date:  2016-03-22       Impact factor: 3.070

6.  Anxiety and Depression among Patients with Uveitis and Ocular Inflammatory Disease at a Tertiary Center in Southern Thailand: Vision-Related Quality of Life, Sociodemographics, and Clinical Characteristics Associated.

Authors:  Wantanee Sittivarakul; Prapaipim Wongkot
Journal:  Ocul Immunol Inflamm       Date:  2018-07-03       Impact factor: 3.070

Review 7.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

8.  Time trade-off: one methodology, different methods.

Authors:  Arthur E Attema; Yvette Edelaar-Peeters; Matthijs M Versteegh; Elly A Stolk
Journal:  Eur J Health Econ       Date:  2013-07

9.  EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes.

Authors:  Mark Oppe; Kim Rand-Hendriksen; Koonal Shah; Juan M Ramos-Goñi; Nan Luo
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

10.  A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma.

Authors:  Fiammetta Maria Bozzani; Yasmene Alavi; Mireia Jofre-Bonet; Hannah Kuper
Journal:  BMC Ophthalmol       Date:  2012-08-21       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.